Kelli Scott1, Cara C Lewis2, C Nathan Marti3. 1. Indiana University, Bloomington, IN; Brown University School of Public Health, Providence, RI. 2. Indiana University, Bloomington, IN; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Washington School of Medicine, Seattle. Electronic address: cara.c.lewis@kp.org. 3. Abacist Analytics, Austin, TX; University of Texas, Austin.
Abstract
OBJECTIVE: Depression is the most prominent mental health disorder among youth and has a profound impact with respect to morbidity and mortality if not addressed. The Treatment for Adolescent Depression Study (TADS) is one of the largest randomized controlled trials that compared the effectiveness of four treatments: cognitive-behavioral therapy (CBT); fluoxetine (FLX); combined cognitive-behavioral and fluoxetine treatment (COMB); and placebo (PBO). However, meaningful heterogeneous treatment courses are masked by these group mean comparisons of treatment impact. The present study sought to characterize the acute phase symptom trajectories of the depressed teens enrolled in TADS and to explore predictors of these trajectories, including TADS treatment condition. METHOD: The TADS sample of 439 adolescent participants diagnosed with major depressive disorder was subjected to growth mixture modeling (GMM) to evaluate subgroups of adolescents with unique trajectories of depression symptom change. RESULTS: Growth mixture modeling revealed three unique classes of adolescents: (1) a high-severity class with early significant improvement; (2) a high-severity class with limited symptom change; and (3) a moderate severity class with late significant improvement. Baseline predictors of class membership included treatment condition, sex, age, stage of change, depression severity, number of comorbid disorders, hopelessness, melancholia, suicidality, and cognitive distortions. CONCLUSION: Results of this study may have implications for the selection of which treatment to use for which depressed adolescent. CLINICAL TRIAL REGISTRATION INFORMATION: Treatment for Adolescents With Depression Study (TADS); https://clinicaltrials.gov/; NCT00006286.
RCT Entities:
OBJECTIVE:Depression is the most prominent mental health disorder among youth and has a profound impact with respect to morbidity and mortality if not addressed. The Treatment for Adolescent Depression Study (TADS) is one of the largest randomized controlled trials that compared the effectiveness of four treatments: cognitive-behavioral therapy (CBT); fluoxetine (FLX); combined cognitive-behavioral and fluoxetine treatment (COMB); and placebo (PBO). However, meaningful heterogeneous treatment courses are masked by these group mean comparisons of treatment impact. The present study sought to characterize the acute phase symptom trajectories of the depressed teens enrolled in TADS and to explore predictors of these trajectories, including TADS treatment condition. METHOD: The TADS sample of 439 adolescent participants diagnosed with major depressive disorder was subjected to growth mixture modeling (GMM) to evaluate subgroups of adolescents with unique trajectories of depression symptom change. RESULTS: Growth mixture modeling revealed three unique classes of adolescents: (1) a high-severity class with early significant improvement; (2) a high-severity class with limited symptom change; and (3) a moderate severity class with late significant improvement. Baseline predictors of class membership included treatment condition, sex, age, stage of change, depression severity, number of comorbid disorders, hopelessness, melancholia, suicidality, and cognitive distortions. CONCLUSION: Results of this study may have implications for the selection of which treatment to use for which depressed adolescent. CLINICAL TRIAL REGISTRATION INFORMATION: Treatment for Adolescents With Depression Study (TADS); https://clinicaltrials.gov/; NCT00006286.
Authors: Benedetto Vitiello; Paul Rohde; Susan Silva; Karen Wells; Charles Casat; Bruce Waslick; Anne Simons; Mark Reinecke; Elizabeth Weller; Christopher Kratochvil; John Walkup; Sanjeev Pathak; Michele Robins; John March Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-12 Impact factor: 8.829
Authors: Betsy Kennard; Susan Silva; Benedetto Vitiello; John Curry; Christopher Kratochvil; Anne Simons; Jennifer Hughes; Norah Feeny; Elizabeth Weller; Michael Sweeney; Mark Reinecke; Sanjeev Pathak; Golda Ginsburg; Graham Emslie; John March Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-12 Impact factor: 8.829
Authors: John Curry; Paul Rohde; Anne Simons; Susan Silva; Benedetto Vitiello; Christopher Kratochvil; Mark Reinecke; Norah Feeny; Karen Wells; Sanjeev Pathak; Elizabeth Weller; David Rosenberg; Betsy Kennard; Michele Robins; Golda Ginsburg; John March Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-12 Impact factor: 8.829
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: Roberto López; Leslie A Brick; Annamarie B Defayette; Emma D Whitmyre; Jennifer Wolff; Elisabeth Frazier; Anthony Spirito; Christianne Esposito-Smythers Journal: J Affect Disord Date: 2020-05-23 Impact factor: 4.839
Authors: Jennifer B Dwyer; Argyris Stringaris; David A Brent; Michael H Bloch Journal: J Child Psychol Psychiatry Date: 2020-02-04 Impact factor: 8.982
Authors: Sian Emma Davies; Sharon A S Neufeld; Eleonore van Sprang; Lizanne Schweren; Rogier Keivit; Peter Fonagy; Bernadka Dubicka; Raphael Kelvin; Nick Midgley; Shirley Reynolds; Mary Target; Paul Wilkinson; Anne Laura van Harmelen; Ian Michael Goodyer Journal: J Child Psychol Psychiatry Date: 2019-10-24 Impact factor: 8.265